HOME >> MEDICINE >> NEWS
AMN107 has potent activity in leukemia resistant to Gleevec

The targeted agent AMN107 can produce dramatic benefits in patients with some forms of leukemia that are resistant to Gleevec, the standard therapy for these cancers, say researchers at The University of Texas M. D. Anderson Cancer Center (meeting abstract #37).

At the 47th Annual Meeting of the American Society of Hematology (ASH), the investigators reported marked improvement in outcome in all three phases of chronic myeloid leukemia (CML) as well as benefit in treating a form of acute lymphocytic leukemia (ALL) that shares the same genetic abnormality as CML, the Philadelphia chromosome.

"This drug is very promising and appears at this point to offer an effective option for patients who do not achieve an optimal response to Gleevec therapy," says Hagop Kantarjian, M.D., professor and chair of the Department of Leukemia.

If additional studies continue to show such results, Kantarjian says, he believes AMN107, which is taken in pill form, "will either replace Gleevec as the standard of care in the future or will be used in combination with it."

Both CML and Philadelphia-positive ALL is caused by the swapping of genetic material in bone marrow stem cells between two chromosomes, which produces an abnormality called the Philadelphia chromosome. This new gene then produces a novel tyrosine kinase (Bcr-Abl) that signals the abnormal cell growth that leads to development of leukemia.

While both Gleevec and AMN107 shut down the activity of Bcr-Abl, laboratory experiments with AMN107 show it is up to 50 times more potent because it binds more efficiently to the enzyme than does Gleevec.

In the phase I clinical trial being reported, 119 patients who were resistant to Gleevec were given AMN107, and in some cases the dose was increased up to twelve fold. The researchers found that the range of response varied, depending on the form of the cancer and the presence of genetic mutations. For example, hematologic response fr
'"/>

Contact: Nancy Jensen
nwjensen@mdanderson.org
713-794-1584
University of Texas M. D. Anderson Cancer Center
10-Dec-2005


Page: 1 2

Related medicine news :

1. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
2. Electric fields have potential as a cancer treatment
3. STAMP system can help professionals to identify potentially violent individuals
4. AMPAKINE compounds a new potential treatment for respiratory depression
5. Herb shows potential to reduce cancer-related fatigue
6. Clinical data suggest potential versatility of ALIMTA-based regimens in lung cancer
7. Women with breast cancer do not get potentially life-saving information, survey reveals
8. Eating cured meats frequently can lead to lower lung function and potential COPD
9. Clinical studies evaluate potential treatments for mouth ulcers
10. Synthetic production of potential pharmaceuticals dramatically simplified by Scripps research team
11. Obesity and environmental chemicals -- New research probes potential link

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: AMN107 has potent activity leukemia resistant Gleevec

(Date:7/28/2014)... HealthDay Reporter MONDAY, July 28, ... milliseconds to look at someone,s face and judge them good-looking ... certain facial features seem to trigger specific first impressions about ... the mouth, for example, appear directly linked to whether someone ... The study findings suggest that first impressions are fairly ...
(Date:7/28/2014)... Nashville, TN (PRWEB) July 28, 2014 ... successful Operation Military June . Renowned LASIK ... Military June" to provide significant funds and public ... active and retired military personnel and their families. ... we will proudly give nearly $5,000 to a ...
(Date:7/28/2014)... News) --,The more chronic medical conditions people have at ... a new study claims. Since nearly four ... at Johns Hopkins Bloomberg School of Public Health in ... in life expectancy are slowing in the United States. ... kidney disease and heart failure is now the norm ...
(Date:7/28/2014)... 28, 2014 SIMpalm helped its ... App is available on iTunes for download . Experience ... Audio Chef allows you to listen and cook along with ... way: simply get out the ingredients and equipment, press play, ... or prepare ingredients ahead of time, just relax and cook ...
(Date:7/28/2014)... Lake City, Utah (PRWEB) July 28, 2014 ... protein powders and drinks, announced that it will be ... drink line of products this summer. The additional flavors ... with clean pure taste-free protein , Inspire Pomegranate Razz ... Vanilla - flavor of soft-serve vanilla cone , Bariatric ...
Breaking Medicine News(10 mins):Health News:Facial Dimensions May Be Key to First Impressions 2Health News:Facial Dimensions May Be Key to First Impressions 3Health News:Shofner Vision Center’s “Operation Military June” Provided Funds For Local Not-For-Profit Organizations Supporting Military And Their Families 2Health News:Shofner Vision Center’s “Operation Military June” Provided Funds For Local Not-For-Profit Organizations Supporting Military And Their Families 3Health News:Chronic Medical Conditions Can Shorten Seniors' Lives: Study 2Health News:Audio Chef Co. Releases Audio Cooking App for iPhone/iPad/iPod touch 2Health News:Audio Chef Co. Releases Audio Cooking App for iPhone/iPad/iPod touch 3Health News:Audio Chef Co. Releases Audio Cooking App for iPhone/iPad/iPod touch 4Health News:Bariatric Eating Announces Three New Protein Shake Flavors 2
(Date:7/28/2014)... Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC ) today ... webcast to discuss financial results for the second quarter of ... 2014 at 4:30 p.m. ET. Conference call ... 2014 Time: 4:30 PM ET Listen via Internet: http://ir.pharmacyclics.com/events.cfm ... A webcast replay will be available on the Pharmacyclics website ...
(Date:7/28/2014)... , July 28, 2014  Dignity Health ... has received the Get With The Guidelines®-Stroke Silver-Plus ... measures outlined by the American Heart Association/American Stroke ... is the number four cause of death and ... the United States , according to ...
(Date:7/28/2014)... Pharmaceuticals, Inc. (NASDAQ: ANTH ), today announced financial ... 30, 2014. Net loss for the three ... $8.3 million for the same period in 2013. The decrease ... in interest expense in the current period.  ... was $15.2 million, compared with net loss of $15.9 million ...
Breaking Medicine Technology:Pharmacyclics Announces Date of Conference call to discuss Financial Results for Second Quarter of 2014 2Dignity Health St. Mary's Medical Center Honored with Quality Achievement Award for Stroke Care 2Dignity Health St. Mary's Medical Center Honored with Quality Achievement Award for Stroke Care 3Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 2Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 3Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 4Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 5Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 6Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 7
Cached News: